{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:43:38Z","timestamp":1791157418457,"version":"4.1.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T00:00:00Z","timestamp":1381104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0076676","type":"journal-article","created":{"date-parts":[[2013,10,7]],"date-time":"2013-10-07T20:59:08Z","timestamp":1381179548000},"page":"e76676","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":72,"title":["Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells"],"prefix":"10.1371","volume":"8","author":[{"given":"Anna","family":"Vavrova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Jansova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliska","family":"Mackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Machacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Haskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Tichotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sterba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Simunek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"26","author":"L Gianni","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"G Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/nar\/gkn937","article-title":"The DNA cleavage reaction of topoisomerase II: wolf in sheep&apos;s clothing","volume":"37","author":"JE Deweese","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"T Simunek","year":"2009","journal-title":"Pharmacol Rep"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0163-7258(90)90088-J","article-title":"Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity","volume":"47","author":"HG Keizer","year":"1990","journal-title":"Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/0929867305666220314194045","article-title":"Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines","volume":"5","author":"BB Hasinoff","year":"1998","journal-title":"Curr Med Chem"},{"key":"ref7","first-page":"4903","article-title":"Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives","volume":"51","author":"K Tanabe","year":"1991","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12012-007-0023-3","article-title":"Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?","volume":"7","author":"BB Hasinoff","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"DB Sawyer","year":"2013","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"S Zhang","year":"2012","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tox.2007.05.016","article-title":"In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity","volume":"237","author":"M Adamcova","year":"2007","journal-title":"Toxicology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V54.3.713.713","article-title":"Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia","volume":"54","author":"R Gallagher","year":"1979","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0003-2697(69)90064-5","article-title":"Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues","volume":"27","author":"F Tietze","year":"1969","journal-title":"Anal Biochem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cbi.2012.03.010","article-title":"Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action","volume":"197","author":"E Mackova","year":"2012","journal-title":"Chem Biol Interact"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","article-title":"Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences","volume":"108","author":"H Glickstein","year":"2006","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4827(76)90447-X","article-title":"Properties of a clonal muscle cell line from rat heart","volume":"98","author":"BW Kimes","year":"1976","journal-title":"Exp Cell Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/mol.64.3.670","article-title":"The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity","volume":"64","author":"BB Hasinoff","year":"2003","journal-title":"Mol Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-003-0498-7","article-title":"The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review","volume":"130","author":"SM Swain","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/abio.2002.5611","article-title":"A review of fluorescence methods for assessing labile iron in cells and biological fluids","volume":"304","author":"BP Esp\u00f3sito","year":"2002","journal-title":"Anal Biochem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/tx100125t","article-title":"Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury","volume":"23","author":"P Bendova","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LCM (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews: 71.","DOI":"10.1002\/14651858.CD003917.pub4"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection","volume":"18","author":"M \u0160t\u011brba","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"KA Wouters","year":"2005","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/abbi.1995.1091","article-title":"Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals","volume":"316","author":"KL Malisza","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6605192","article-title":"Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death","volume":"101","author":"O Popelov\u00e1","year":"2009","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"E Martin","year":"2009","journal-title":"Toxicology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CT:3:2:89","article-title":"Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria","volume":"3","author":"BB Hasinoff","year":"2003","journal-title":"Cardiovasc Toxicol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-003-0619-7","article-title":"Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide","volume":"52","author":"PE Schroeder","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"YL Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00204-010-0615-8","article-title":"In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity","volume":"85","author":"A V\u00e1vrov\u00e1","year":"2011","journal-title":"Arch Toxicol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00001813-199607000-00011","article-title":"The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells","volume":"7","author":"BB Hasinoff","year":"1996","journal-title":"Anticancer Drugs"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology &amp; Therapeutics 99: 167 \u2212 181.","DOI":"10.1016\/S0163-7258(03)00058-5"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1999.17.10.3362","article-title":"Current status of oral anticancer drugs in Japan","volume":"17","author":"Y Fujiwara","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002800050805","article-title":"MST-16, a novel derivative of bis(2,6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines","volume":"42","author":"S Inutsuka","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2210-5-11","article-title":"Anti-proliferative effects, cell cycle G2\/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines","volume":"5","author":"DY Lu","year":"2005","journal-title":"BMC Pharmacol"},{"key":"ref37","first-page":"1161","article-title":"Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin","volume":"13","author":"H Minderman","year":"1993","journal-title":"Anticancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/0006-2952(85)90368-5","article-title":"Initial mechanistic studies with merbarone (NSC 336628)","volume":"34","author":"DA Cooney","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q","article-title":"Eukaryotic DNA topoisomerase II\u00df","volume":"20","author":"CA Austin","year":"1998","journal-title":"Bioessays"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.biocel.2012.03.005","article-title":"DNA topoisomerase II\u03b2: a player in regulation of gene expression and cell differentiation","volume":"44","author":"A V\u00e1vrov\u00e1","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1046\/j.1432-1033.2003.03814.x","article-title":"A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria","volume":"270","author":"RL Low","year":"2003","journal-title":"Eur J Biochem"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0076676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T04:21:29Z","timestamp":1688530889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0076676"}},"subtitle":[],"editor":[{"given":"Rajesh","family":"Mohanraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,7]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0076676","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,7]]}}}